Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: AgeneBio

Baltimore biopharm hires neuroscience veteran Mohs as VP (access required)

Baltimore-based biopharmaceutical company AgeneBio has appointed Richard Mohs as vice president of clinical development. Mohs has more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab ...

Read More »

Baltimore biopharm to present at investor conference (access required)

Baltimore-based AgeneBio, a biopharmaceutical company developing therapeutics for patients with neurodegeneration, plans to make a presentation at the BIO Investor Forum later this month in San Francisco. The conference will be held Oct. 20 and 21 at the Parc 55. ...

Read More »

AgeneBio receives Alzheimer’s grant (access required)

The Alzheimer’s Drug Discovery Foundation has given a $900,000 grant to AgeneBio, a Baltimore-based pharmaceutical company, the company announced Wednesday. The funds will help AgeneBio develop AGB101, a treatment for amnestic mild cognitive impairment, the pre-dementia stage of Alzheimer’s disease. ...

Read More »